Central serous chorioretinopathy

Ophthalmologica. 2014;232(2):65-76. doi: 10.1159/000360014. Epub 2014 Apr 26.

Abstract

The pathogenesis of central serous chorioretinopathy (CSC) is still not fully understood. The involvement of corticosteroids is undisputed, although their exact role has not been clarified; other parts of the underlying mechanism of CSC have been mainly elucidated by imaging techniques such as fluorescein and indocyanine green angiography. Even though most cases of CSC are self-limiting, severe as well as recurrent courses exist, and for these patients only a limited number of treatment options are available: laser photocoagulation, with a risk of scotoma and choroidal neovascularization, and photodynamic therapy. In this review article, we give an overview of its epidemiology, the current understanding of its pathogenesis as well as systemic and ocular risk factors. We illuminate modern diagnostic tools as well as current treatment options in the context of CSC, particularly in the light of a better understanding of corticosteroids and their receptors involved in its pathogenesis.

Publication types

  • Review

MeSH terms

  • Central Serous Chorioretinopathy* / diagnosis
  • Central Serous Chorioretinopathy* / epidemiology
  • Central Serous Chorioretinopathy* / etiology
  • Central Serous Chorioretinopathy* / therapy
  • Fluorescein Angiography
  • Humans
  • Laser Coagulation
  • Risk Factors